VCA Stocks

OptiMedica Corp., a global ophthalmic device company, has announced the receipt of $16 million in Series C financing.  OptiMedica holds the exclusive license to the PASCAL® (PAttern SCAn Laser) method of photocoagulation and its associated technologies, which are approved by the U.S. Food and Drug Administration for treatment of a variety of retinal conditions. Clinical experience with PASCAL has demonstrated unmatched precision, efficiency and patient comfort.